Johnson & Johnson (JNJ): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Johnson & Johnson ( JNJ) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.8%. By the end of trading, Johnson & Johnson rose $0.97 (1.1%) to $88.53 on average volume. Throughout the day, 8,473,312 shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9,456,500 shares. The stock ranged in a price between $87.85-$88.58 after having opened the day at $88.14 as compared to the previous trading day's close of $87.56. Other companies within the Drugs industry that increased today were: NanoString Technologies ( NSTG), up 70.6%, GW Pharmaceuticals PLC ADR ( GWPH), up 53.9%, XenoPort ( XNPT), up 17.1% and Galectin Therapeutics ( GALT), up 15.3%.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $245.6 billion and is part of the health care sector. Shares are up 24.3% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Neurocrine Biosciences ( NBIX), down 29.7%, Chemocentryx ( CCXI), down 24.3%, Peregrine Pharmaceuticals ( PPHM), down 6.6% and Genvec ( GNVC), down 6.2% , were all laggards within the drugs industry with Valeant Pharmaceuticals International ( VRX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists